Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Receivables (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Change in Receivables data on record, last reported at $12.4 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 29.34% year-over-year to $12.4 million; the TTM value through Dec 2025 reached $38.3 million, up 27.07%, while the annual FY2025 figure was $38.3 million, 27.07% up from the prior year.
  • Change in Receivables reached $12.4 million in Q4 2025 per TARS's latest filing, down from $14.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.0 million in Q1 2021 and bottomed at -$20.0 million in Q3 2021.
  • Average Change in Receivables over 5 years is $4.4 million, with a median of $438000.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: plummeted 58723.53% in 2021, then skyrocketed 7424.56% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $73000.0 in 2021, then plummeted by 664.38% to -$412000.0 in 2022, then soared by 2832.77% to $11.3 million in 2023, then skyrocketed by 56.33% to $17.6 million in 2024, then decreased by 29.34% to $12.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $12.4 million in Q4 2025, $14.3 million in Q3 2025, and -$4.1 million in Q2 2025.